MA46436A - Compositions comprenant de la relaxine et leurs méthodes d'utilisation - Google Patents
Compositions comprenant de la relaxine et leurs méthodes d'utilisationInfo
- Publication number
- MA46436A MA46436A MA046436A MA46436A MA46436A MA 46436 A MA46436 A MA 46436A MA 046436 A MA046436 A MA 046436A MA 46436 A MA46436 A MA 46436A MA 46436 A MA46436 A MA 46436A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- compositions including
- including relaxin
- relaxin
- compositions
- Prior art date
Links
- 102000003743 Relaxin Human genes 0.000 title 1
- 108090000103 Relaxin Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2221—Relaxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M3/00—Medical syringes, e.g. enemata; Irrigators
- A61M3/005—Medical syringes, e.g. enemata; Irrigators comprising means for injection of two or more media, e.g. by mixing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/07—Proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662405795P | 2016-10-07 | 2016-10-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46436A true MA46436A (fr) | 2019-08-14 |
Family
ID=60186382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046436A MA46436A (fr) | 2016-10-07 | 2017-10-09 | Compositions comprenant de la relaxine et leurs méthodes d'utilisation |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11723957B2 (fr) |
| EP (2) | EP3522911B1 (fr) |
| AU (2) | AU2017339536B2 (fr) |
| CA (1) | CA3078452A1 (fr) |
| DK (1) | DK3522911T3 (fr) |
| MA (1) | MA46436A (fr) |
| WO (1) | WO2018068047A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102533456B1 (ko) | 2016-05-18 | 2023-05-17 | 모더나티엑스, 인크. | 릴랙신을 인코딩하는 폴리뉴클레오타이드 |
| PE20191716A1 (es) | 2017-02-08 | 2019-12-05 | Bristol Myers Squibb Co | Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos |
| WO2021237061A1 (fr) * | 2020-05-22 | 2021-11-25 | Trustees Of Boston University | Méthodes et compositions pour le traitement d'une maladie fibrotique |
| KR20240110824A (ko) | 2021-11-11 | 2024-07-16 | 테크토닉 세러퓨틱스 인코포레이티드 | 릴랙신-2 융합 단백질 유사체 및 이의 사용 방법 |
| IL324680A (en) | 2023-05-18 | 2026-01-01 | Tectonic Operating Company Inc | Relaxin-2 fusion protein analogs and methods of using them |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2051375C (fr) | 1989-05-04 | 2000-09-12 | Dennis J. Henner | Procede et compositions pour l'isolement de la relaxine humaine |
| DE69233069T2 (de) * | 1991-03-15 | 2003-11-27 | Amgen Inc., Thousand Oaks | Pegylation von polypeptiden |
| US6251863B1 (en) * | 1998-09-08 | 2001-06-26 | Samuel K. Yue | Method of preventing and treating symptoms of aging and neurodegenerative dysfunctions with relaxin |
| ITFI20030328A1 (it) * | 2003-12-24 | 2005-06-25 | Mario Bigazzi | Uso della relaxina come adiuvante nella differenziazione |
| US20080269762A1 (en) * | 2007-04-25 | 2008-10-30 | Biomet Manufacturing Corp. | Method and device for repair of cartilage defects |
| EP3572091B1 (fr) * | 2010-08-17 | 2023-12-13 | Ambrx, Inc. | Polypeptides de relaxine modifiés et leurs utilisations |
| US8404268B2 (en) | 2010-10-26 | 2013-03-26 | Kyphon Sarl | Locally targeted anti-fibrotic agents and methods of use |
| EP2755691B1 (fr) * | 2011-09-07 | 2018-08-22 | Prolynx LLC | Hydrogels à réticulation biodégradable |
| WO2015067791A1 (fr) * | 2013-11-11 | 2015-05-14 | Ascendis Pharma Relaxin Division A/S | Promédicaments à bae de relaxine |
| UA123432C2 (uk) * | 2014-07-30 | 2021-04-07 | Нджм Біофармасьютікалз, Інк. | Димер та спосіб його застосування для лікування метаболічних розладів |
| PT3387019T (pt) * | 2015-12-09 | 2022-01-14 | Scripps Research Inst | Proteínas de fusão de imunoglobulina de relaxina e métodos de uso |
-
2017
- 2017-10-09 WO PCT/US2017/055799 patent/WO2018068047A1/fr not_active Ceased
- 2017-10-09 DK DK17791235.9T patent/DK3522911T3/da active
- 2017-10-09 EP EP17791235.9A patent/EP3522911B1/fr active Active
- 2017-10-09 US US16/339,659 patent/US11723957B2/en active Active
- 2017-10-09 CA CA3078452A patent/CA3078452A1/fr active Pending
- 2017-10-09 AU AU2017339536A patent/AU2017339536B2/en active Active
- 2017-10-09 MA MA046436A patent/MA46436A/fr unknown
- 2017-10-09 EP EP21212781.5A patent/EP4056196A1/fr active Pending
-
2023
- 2023-06-28 US US18/215,317 patent/US20240173383A1/en active Pending
-
2025
- 2025-03-19 AU AU2025202009A patent/AU2025202009A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11723957B2 (en) | 2023-08-15 |
| US20190282665A1 (en) | 2019-09-19 |
| WO2018068047A1 (fr) | 2018-04-12 |
| AU2017339536B2 (en) | 2024-12-19 |
| US20240173383A1 (en) | 2024-05-30 |
| DK3522911T3 (da) | 2022-03-07 |
| AU2017339536A1 (en) | 2019-05-23 |
| WO2018068047A8 (fr) | 2019-03-21 |
| AU2025202009A9 (en) | 2025-04-17 |
| AU2025202009A1 (en) | 2025-04-10 |
| EP4056196A1 (fr) | 2022-09-14 |
| EP3522911B1 (fr) | 2021-12-08 |
| EP3522911A1 (fr) | 2019-08-14 |
| CA3078452A1 (fr) | 2018-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3383430A4 (fr) | Anticorps et leurs méthodes d'utilisation | |
| MA50957A (fr) | Anticorps anti-tigit et leurs méthodes d'utilisation | |
| MA45123A (fr) | Anticorps anti-tim-3 et leurs méthodes d'utilisation | |
| EP3319611A4 (fr) | Oxystérols et leurs méthodes d'utilisation | |
| EP3700527A4 (fr) | Inhibiteurs de papd5 et leurs méthodes d'utilisation | |
| MA43387A (fr) | Anticorps anti-gitr et leurs méthodes d'utilisation | |
| EP3436022A4 (fr) | Oxystérols et leurs méthodes d'utilisation | |
| EP3368016A4 (fr) | Polysaccharides réduits et oxydés et leurs méthodes d'utilisation | |
| MA44955A (fr) | Anticorps anti-tau et leurs méthodes d'utilisation | |
| EP3525583A4 (fr) | Anticorps anti-c1s et leurs méthodes d'utilisation | |
| EP3463381A4 (fr) | Dérivés nucléotidiques et leurs méthodes d'utilisation | |
| MA42925A (fr) | Anticorps anti-tigit et méthodes d'utilisation | |
| MA48595A (fr) | Anticorps anti-tau et leurs méthodes d'utilisation | |
| MA42243A (fr) | Anticorps de facteur xi et méthodes d'utilisation | |
| MA43284A (fr) | Composés et leurs méthodes d'utilisation | |
| EP3356381A4 (fr) | Dérivés nucléotidiques et leurs méthodes d'utilisation | |
| EP3337517A4 (fr) | Conjugués anticorps-médicaments anti-dll3 et méthodes d'utilisation | |
| MA46566A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA46565A (fr) | Oxystérols et leurs procédés d'utilisation | |
| EP3435956A4 (fr) | Compositions photo-stabilisées et leurs procédés d'utilisation | |
| EP3684369A4 (fr) | Compositions d'anticorps a33 et leurs méthodes d'utilisation en radioimmunothérapie | |
| EP3634390A4 (fr) | Compositions antimicrobiennes comprenant des cannabinoïdes et leurs méthodes d'utilisation | |
| MA42409A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA54851A (fr) | Oxystérols et leurs procédés d'utilisation | |
| EP3419656A4 (fr) | Compositions de néoantigène et leurs méthodes d'utilisation en immuno-oncothérapie |